Eli Lilly
LLY Mega CapHealthcare · Drug Manufacturers - General
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Eli Lilly en bref
Eli Lilly (LLY) is currently trading at 996,05 € with a market capitalization of 888,2 Md €. The trailing P/E ratio stands at 40.81x, with a forward P/E of 25.5x. The 52-week range spans from 540,82 € to 1 083,28 €; the current price is 8.1% below the yearly high. Year-over-year revenue growth stands at +55.5%. The net profit margin stands at 34.99%.
💰 Dividende
Eli Lilly pays an annual dividend of 6,00 € per share, representing a yield of 0.6%. The payout ratio stands at 22.13%.
📊 Avis des analystes
26 analystes évaluent Eli Lilly (LLY) au consensus : Acheter. L'objectif de cours moyen est de 1 107,13 €, soit un potentiel de +11.15% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 736,95 € à 1 387,20 €.
Eli Lilly : la thèse d'investissement en détail
Eli Lilly (LLY) operates in the Healthcare — specifically Drug Manufacturers - General — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 55.5% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 82.83%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Return on equity of 107.46% places management among the most capital-efficient operators in the public market — every euro of shareholder capital is working hard.
Le scénario baissier
Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The EV/EBITDA multiple of 29.34x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The forward P/E of 25.5x is meaningfully below the trailing 40.81x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 55.5% sur un an
- Rentable avec une marge nette de 34.99%
- Rentabilité élevée des capitaux propres (107.46% ROE)
- Marge brute élevée de 82.83% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Free cash flow positif
- –Actuellement jugée surévaluée
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, higher leverage relative to equity.
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Eli Lilly?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news